Hengrui Pharmaceutical (01276) intends to license the first innovative drug project, HRS-1893, to Braveheart Bio for a fee to expand into overseas markets.

Wisdom Financial APP News, Jiangsu Hengrui Medicine (01276) announced that the company has reached an agreement with American company Braveheart Bio, Inc. (hereinafter referred to as "Braveheart Bio"), to license the self-owned intellectual property innovative drug HRS-1893 project to Braveheart Bio for a fee.